Résumé
Background : Nebivolol is a third-generation highly selective b1-blocker with additional endothelial nitric oxide (NO) mediated vasodilating activity. This property may potentiate the blood pressure-lowering effect of Nebivolol. Nebivolol is also claimed to have neutral or favourable effect on carbohydrate metabolism and lipid profile. Therefore this study was conducted to evaluate effects of Nebivolol on different biochemical parameters in essential hypertensive patients. Materials and Methods : 21 newly diagnosed patients of either sex with essential hypertension were included in the study. Patients having co-morbidities e.g. Diabetes mellitus, hyperlipidemia, gout, pregnant females were excluded from the study. Baseline readings of lipid profile, serum electrolytes, fasting blood sugar and uric acid were recorded before starting Nebivolol drug therapy. Same biochemical tests were repeated after six months drug treatment. Results and Observation : After comparing the means there is increase in total cholesterol, LDL, Serum electrolytes, blood sugar levels but this increase is within normal limits and is not statistically significant. While there is decrease in TG level but statistically not significant. No significant change in HDL, uric acid levels. Conclusion : Nebivolol is a unique, highly selective b1-blocker due to its neutral metabolic properties and is potentially safe over conventional b-blockers.
Sujets)
Adolescent , Antagonistes bêta-adrénergiques/pharmacologie , Adulte , Sujet âgé , Benzopyranes/analogues et dérivés , Benzopyranes/pharmacologie , Glycémie , Comorbidité , Électrolytes/sang , Éthanolamines/analogues et dérivés , Éthanolamines/pharmacologie , Femelle , Humains , Hypertension artérielle/effets des médicaments et des substances chimiques , Hypertension artérielle/physiologie , Lipides/sang , Lipoprotéines HDL/sang , Lipoprotéines LDL/sang , Mâle , Adulte d'âge moyen , Acide urique/sang , Jeune adulteRésumé
1,2-dihydropyrano [3,2-g] [1] benzopyran-5-one derivatives IV a,b, VII and 1,2,3,4-tetrahydropyrano [3,2,g] [1] benzopypran-5-one derivatives VIII a-k were synthesized from the o-hydroxyaldehyde II. Compounds IVb, V, VIb, VII, VIIIb,c were tested for analgesic anti-inflammatory and ulcerogenic effects. Compounds VIIIb,c, VIb and VII were found to be potent analgesics with minimal ulcerogenic effect except VIb. None of the tested compounds was found to have anti-inflammatory activity